Position in FULC
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$1,048,212
-$79,496 QoQ
Shares Held
136,664
+37.1% QoQ
Ownership
0.205%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#50
of 168 holders
Holding Since
Jun 2022
9 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in FULC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026GSA CAPITAL PARTNERS LLP holds $99,952,720 across 160 Biotechnology names. FULC ranks #39 (1.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,831 | $2,959,983 | |
| 2 | ARDX |
Ardelyx, Inc.
|
473,061 | $2,833,635 | |
| 3 | NTLA |
Intellia Therapeutics, Inc.
|
178,301 | $2,285,818 | |
| 4 | NUVB |
Nuvation Bio Inc.
|
495,792 | $2,126,947 | |
| 5 | RXRX |
Recursion Pharmaceuticals, Inc.
|
669,568 | $2,055,573 | |
| 6 | WVE |
Wave Life Sciences Ltd.
|
282,719 | $2,049,712 | |
| 7 | SRPT |
Sarepta Therapeutics, Inc.
|
90,960 | $1,979,289 | |
| 8 | IOVA |
Iovance Biotherapeutics, Inc.
|
557,085 | $1,955,368 |
All Filings in FULC
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,048,212 | 136,664 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $1,127,708 | 99,709 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $1,067,825 | 116,068 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $224,033 | 32,563 | Shares | Sole | 2025-07-22 | |
| 2024-09-30 | $61,196 | 17,142 | Shares | Sole | 2024-11-05 | |
| 2024-06-30 | $838,370 | 135,221 | Shares | Sole | 2024-08-15 | |
| 2024-03-31 | $143,129 | 15,162 | Shares | Sole | 2024-05-03 | |
| 2022-09-30 | $144,641 | 17,879 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $111,827 | 22,822 | Shares | Sole | 2022-08-09 | |
| No filing history on record for this holder in this stock. | ||||||